The company’s allogeneic (off-the-shelf) cell platform utilises induced pluripotent stem cells (iPSCs) generated from donated cord blood, which can be differentiated into NK cells, T cells, and other immune system cells. Cartherics' lead product, CTH-401, is an investigational allogeneic iPSC-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy designed to target solid tumours. Following a successful pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA), CTH-401 is set to enter clinical trials for ovarian cancer in 2025. Subject to early clinical data, CTH-401 will subsequently enter a basket trial targeting other TAG-72+ solid cancers. Prof. Alan Trounson, CEO of Cartherics, sheds light on iPSCs for CAR-T therapies, the future of immunotherapies, and the CGT landscape in the APAC region. Edited excerpts:
Could you explain more about the advantages of using iPSCs from cord blood for creating your ‘off-the-shelf’ CAR-NK and CAR-T therapies?
Umbilical cord blood contains pristine blood cells that have very few spontaneous or induced mutations, can be selected for homozygosity at the HLA locus, that provide the opportunity for transplant compatibility and can be turned into iPSCs that are immortal and can be directed into any cell of the body. These iPSCs can be easily geneedited and have exact editing and freedom from genetic changes by clonal derivation as a therapeutic product free of potential oncogenic inducers. The cells produced are exact clones of each other, much like a drug product. This can only be achieved with pluripotent stem cells. Directing the gene-edited iPSCs into CAR-T and CAR-NK products involves a proprietary method as is the manufacturing process. Consequently, we can use CAR-NK cells for allogeneic (off-the-shelf) therapy. CAR-T cells produced this way need further alteration for allogeneic therapy.
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Nov 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Nov 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Inventia announces groundbreaking advancement in 3D cell culture technology
Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.
Aphra names Justin Untersteiner as CEO
The Australian Health Practitioner Regulation Agency (Ahpra) has appointed Justin Untersteiner as Chief Executive Officer (CEO).
WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls
The World Health Organization (WHO) has signed a Memorandum of Understanding (MoU) with Siriraj Hospital, Mahidol University, Thailand, to strengthen collaboration on trauma, injury, and fall prevention across the WHO South-East Asia Region to address the growing health, social, and economic challenges posed by these issues.
Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services
Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20 per cent retained by PF.
PanopticAI gets US FDA clearance for contactless vital signs monitoring software
PanopticAI, a startup in remote patient monitoring space, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its contactless vital signs monitoring software.
Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma
In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers.
Axel Klarmeyer joins as CEO at Chamlion International
China-based Chamlion, a pioneer in integrated dental 3D printing solutions, has announced the appointment of Axel Klarmeyer as the Chief Executive Officer (CEO) of Chamlion International, overseeing the company's international business operations.
World Bank supports Bosnia and Herzegovina in strengthening healthcare
The World Bank’s Board of Executive Directors has approved a $75 million Second Health Sectors Programmatic Development Policy Loan for Bosnia and Herzegovina (BiH).
GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs
The Global Health Innovative Technology (GHIT) Fund, headquartered in Japan, has announced a total investment of approximately JPY 2 billion ($12.7 million) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.
NIH to lead implementation of National Plan to End Parkinson's Act in US
With support from the US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Jennifer Wexton National Plan to End Parkinson’s Act, which was signed into law on July 2, 2024.
